E-viri
Recenzirano
Odprti dostop
-
Stone, Gregg W.; Farkouh, Michael E.; Lala, Anuradha; Tinuoye, Elizabeth; Dressler, Ovidiu; Moreno, Pedro R.; Palacios, Igor F.; Goodman, Shaun G.; Esper, Rodrigo B.; Abizaid, Alexandre; Varade, Deepak; Betancur, Juan F.; Ricalde, Alejandro; Payro, Gerardo; Castellano, José María; Hung, Ivan FN; Nadkarni, Girish N.; Giustino, Gennaro; Godoy, Lucas C.; Feinman, Jason; Camaj, Anton; Bienstock, Solomon W.; Furtado, Remo H.M.; Granada, Carlos; Bustamante, Jessica; Peyra, Carlos; Contreras, Johanna; Owen, Ruth; Bhatt, Deepak L.; Pocock, Stuart J.; Fuster, Valentin
Journal of the American College of Cardiology, 03/2023Journal Article
Condensed abstract: We randomized 3398 patients hospitalized with COVID-19 not yet requiring intensive care unit (ICU) management to prophylactic-dose enoxaparin, therapeutic-dose enoxaparin or therapeutic-dose apixaban at 76 centers in 10 countries. The 30-day primary composite outcome of all-cause mortality, requirement for ICU level-of-care, systemic thromboembolism, or ischemic stroke was not significantly reduced in the combined therapeutic-dose anticoagulation groups compared with prophylactic-dose anticoagulation. However, fewer patients who were treated with therapeutic-dose anticoagulation required intubation or died. The benefits of therapeutic-dose anticoagulation were most strongly evident in higher-risk patients.
